The independent pharmacy guide to the 25% aberrancy line
The short answer
Caremark reviews the share of a pharmacy's business tied to a defined list of aberrant products, measured against a 25% line. This guide explains, in plain English, what that line is, how the two tests work, and how to read your own numbers so nothing is a surprise at reconciliation.
What the 25% line refers to
Pharmacy network materials may address dispensing tied to defined aberrant products under payer-specific terms. PharmaFix uses a 25% reference line for report review; current payer documents and the pharmacy's agreement control, and the result does not predict payer action.
PharmaFix does not set that line and does not speak for any PBM. It helps you read your own report against the same idea, so you can review your position on your own schedule.
The two tests, tracked together
- The dollar test looks at aberrant paid dollars as a share of total paid dollars.
- The claim-count test looks at aberrant claims as a share of total claims.
A pharmacy can read lower on one test and higher on the other because a high-dollar aberrant claim can move the paid-dollar rate while barely changing the count rate. Review both as report-based estimates and compare them with current payer documents.
Effective rate and room remaining
The displayed rate is the cumulative aberrant share for the selected report month. Room remaining is a mathematical estimate of the distance to a 25% reference line under the analyzer's assumptions. It is not permission or a recommendation to add claims, products, or dispensing activity.
Why it matters
The displayed share is cumulative for the selected calendar month, so earlier report activity affects later month-to-date rates. Reviewing at consistent points can make changes in the report easier to see. The analyzer does not recommend changes to dispensing, billing, or claim activity.
Key terms
| Term | Meaning |
|---|---|
| Aberrant NDC | A product, identified by its 11-digit NDC, on a defined aberrant-product list networks watch. |
| Dollar test | Aberrant paid dollars divided by total paid dollars for the month. |
| Claim-count test | Aberrant claims divided by total claims for the month. |
| Effective rate | Your cumulative aberrant share for the month so far, on either test. |
| Room remaining | A mathematical estimate of the distance to the 25% reference line under the analyzer's assumptions. |
| The 25% reference line | A comparison point used by this analyzer; current payer documents and the pharmacy's agreement control. |
A worked example
Suppose a report shows $100,000 in total paid amounts and $18,000 tied to matched aberrant NDCs. The displayed paid-dollar rate is 18%. The room figure is derived algebraically because any hypothetical added amount would change both numerator and denominator. This example explains the math only; it is not a forecast or dispensing recommendation.
Common mistakes
- Averaging daily percentages instead of dividing cumulative totals — the test reads month-to-date sums, not a mean of daily rates.
- Watching only the dollar test and missing a climbing claim-count share, or the reverse.
- Checking once at month end, when most volume is booked and little can change.
- Treating the 25% line as an official guarantee rather than a threshold to monitor.
- Using a stale aberrant-NDC list, so recent additions are missed.
How PharmaFix fits
Upload your PrimeRx or Caremark report and PharmaFix estimates both tests, your effective rate, and your room remaining for the month. It is a read on your own data to support internal review, not advice and not a guarantee of any outcome.
Start here
The pages and articles below break each piece down. If you would rather just see your number, the analyzer reads your existing report and shows where you stand.
Frequently asked questions
Is the 25% line an official rule I can rely on?
Treat it as a widely-discussed threshold, not legal or clinical advice. Networks set and change their own terms. PharmaFix helps you read your own report against the concept so you can review internally; it does not speak for any PBM.
Does staying under 25% guarantee anything?
No. No tool can guarantee an outcome with a PBM. PharmaFix helps you monitor and estimate your position so you are not caught off guard; decisions and any follow-up remain yours.
Which test matters more, dollars or claims?
Both are worth watching. A single high-dollar aberrant claim can move the dollar test on its own, while the claim-count test reflects how often aberrant products appear. PharmaFix shows both.
Estimate your report's position against the 25% reference line
Current checkout is test mode. Upload only an authorized PrimeRx or Caremark report without direct patient identifiers. PharmaFix calculates report-based rates and is designed not to retain report rows or results.